Fresh analysis indicates that people who come off blockbuster GLP-1 drugs like Mounjaro or Wegovy tend to recover shed pounds far faster than those who stop traditional diet and exercise plans.
Findings released in a major medical journal demonstrates that while overweight people can lose substantial amounts of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.
"Individuals purchasing these medications should be informed of the potential of quick weight regain when the treatment concludes," stated researcher Dr. Susan Jebb.
That rate of regain implies a reversion to starting mass within about a year and a half.
Comparing Approaches
The analysis, which examined 37 of trials involving over 9,000 of participants, contrasted the effects of the injectable medications with conventional dieting.
The team note that individuals who lose weight through lifestyle changes alone typically see a less rapid weight regain—perhaps 0.1 kg a month—once they finish.
Understanding the Rapid Regain
Nutrition scientists propose the way of the drugs accounts for the accelerated rebound.
These medications imitate a natural hormone called GLP-1, which controls appetite.
"Long-term administration of GLP-1 concentrations far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics specialist.
"Withdrawal of this GLP-1 'fix' results in hunger is no longer kept in check, making excessive eating much more probable."
A Chronic Condition?
Medical guidelines advise the injections for people with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, considering the likelihood of relapse, the therapy is often life-long.
This perspective is echoed by pharmaceutical companies, who say that the results "highlight the chronic nature of obesity," similar to managing conditions like high blood pressure.
User Accounts
Individuals who have discontinued the jabs describe a intense return of hunger.
"I experienced a trigger that goes on and you're instantly starving," recalled a patient.
This challenge is compounded if patients have not developed lasting lifestyle or habit modifications during therapy.
Significant Adoption
Survey data suggest that a significant number of adults in the UK have used these injections in the past year, with desire remaining high.
- Use is greater among females than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than the NHS.
Finally, clinicians stress that while the jabs are potent agents for shedding pounds, they are not a permanent fix and lasting health benefits likely depends on combined lifestyle changes.
